Taiho Pharmaceutical to expand ADC portfolio with Araris Biotech acquisition
Taiho Pharmaceutical is acquiring Araris Biotech for $1.14 billion, strengthening its ADC oncology pipeline. Discover how this deal is shaping the future of cancer treatment. Read More
Cullinan Oncology to sell Cullinan Pearl to Taiho Pharmaceutical for $275m
American biopharma company Cullinan Oncology has agreed to sell its subsidiary Cullinan Pearl to Taiho Pharmaceutical, a Japanese specialty pharma company, for $275 million. Cullinan ... Read More